BAJAJ BROKING

Notification close image
No new Notification messages
card image
Amanta Healthcare Ltd IPO
Apply for the Amanta Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

1186

543245

GLAND

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GLAND PHARMA LIMITED performance

Today’s low

Today’s high

₹ 1852.60 ₹ 1904.00
₹ 1871.50

52 week low

52 week high

₹ 1277.80 ₹ 2131.00
₹ 1871.50

Open Price

₹ 1887.50

Prev. Close

₹ 1886.80

Volume (Shares)

140575.00

Total traded value

₹ 2630.86

Upper Circuit

₹ 2264.10

Lower Circuit

₹ 1509.50

info

GLAND PHARMA LIMITED Share Price Update

As of the latest trading session, GLAND PHARMA LIMITED share price is currently at ₹ 1871.5, which is down by ₹ -15.30 from its previous closing. Today, the stock has fluctuated between ₹ 1852.60 and ₹ 1904.00. Over the past year, GLAND PHARMA LIMITED has achieved a return of 1.21 %. In the last month alone, the return has been -10.96 %. Read More...

Investment Returns

Over 1 Month -10.96% Over 3 Months 18.58% Over 6 Months 20.52% Over 1 Year 1.21%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GLAND PHARMA LIMITED fundamentals


  • Market cap (Cr)

    30,834.20

  • P/E Ratio (TTM)

    27.07

  • Beta

    0.82

  • Book Value / share

    592.09

  • Return on equity

    11.62%

  • EPS (TTM)

    68.96

  • Dividend yield

    0.96%

  • Net profit/quarter (Cr)

    269.26

info icon alternate text
  • Market cap (Cr)

    30,760.00

  • P/E Ratio (TTM)

    27.07

  • Beta

    0.81

  • Book Value / share

    592.09

  • Return on equity

    11.62%

  • EPS (TTM)

    68.96

  • Dividend yield

    0.96%

  • Net profit/quarter (Cr)

    269.26

info icon alternate text

GLAND PHARMA LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 1038.84
Operating Expense 731.20
Net Profit 269.26
Net Profit Margin (%) 25.91
Earnings Per Share (EPS) 16.34
EBITDA 413.59
Effective Tax Rate (%) 25.69
Particulars MAR 2025 (Values in Cr)
Revenue 1030.35
Operating Expense 682.75
Net Profit 290.00
Net Profit Margin (%) 28.14
Earnings Per Share (EPS) 17.60
EBITDA 437.84
Effective Tax Rate (%) 25.89
Particulars DEC 2024 (Values in Cr)
Revenue 1010.78
Operating Expense 681.71
Net Profit 295.12
Net Profit Margin (%) 29.19
Earnings Per Share (EPS) 17.91
EBITDA 456.21
Effective Tax Rate (%) 25.12
Particulars SEP 2024 (Values in Cr)
Revenue 1062.99
Operating Expense 740.97
Net Profit 281.71
Net Profit Margin (%) 26.50
Earnings Per Share (EPS) 17.10
EBITDA 421.61
Effective Tax Rate (%) 25.83
Particulars JUN 2024 (Values in Cr)
Revenue 1012.02
Operating Expense 760.19
Net Profit 222.92
Net Profit Margin (%) 22.02
Earnings Per Share (EPS) 13.53
EBITDA 342.05
Effective Tax Rate (%) 25.76
Particulars MAR 2025 (Values in Cr)
Revenue 4116.15
Operating Expense 2865.64
Net Profit 1089.75
Net Profit Margin (%) 26.47
Earnings Per Share (EPS) 66.15
EBITDA 1657.69
Effective Tax Rate (%) 25.64
Particulars MAR 2024 (Values in Cr)
Revenue 4167.43
Operating Expense 2928.59
Net Profit 1043.33
Net Profit Margin (%) 25.03
Earnings Per Share (EPS) 63.35
EBITDA 1575.44
Effective Tax Rate (%) 25.76
Particulars MAR 2023 (Values in Cr)
Revenue 3616.53
Operating Expense 2752.12
Net Profit 775.83
Net Profit Margin (%) 21.45
Earnings Per Share (EPS) 47.12
EBITDA 1202.55
Effective Tax Rate (%) 25.99
Particulars MAR 2022 (Values in Cr)
Revenue 4400.71
Operating Expense 3005.60
Net Profit 1212.16
Net Profit Margin (%) 27.54
Earnings Per Share (EPS) 73.84
EBITDA 1734.58
Effective Tax Rate (%) 25.13
Particulars MAR 2021 (Values in Cr)
Revenue 3462.88
Operating Expense 2262.79
Net Profit 997.01
Net Profit Margin (%) 28.79
Earnings Per Share (EPS) 63.07
EBITDA 1437.04
Effective Tax Rate (%) 25.30
Particulars MAR 2025 (Values in Cr)
Book Value / Share 555.40
ROE % 7.82
ROCE % 11.67
Total Debt to Total Equity 0.04
EBITDA Margin 26.40
Particulars MAR 2024 (Values in Cr)
Book Value / Share 529.65
ROE % 9.26
ROCE % 13.44
Total Debt to Total Equity 0.02
EBITDA Margin 26.54
Particulars MAR 2023 (Values in Cr)
Book Value / Share 483.23
ROE % 10.33
ROCE % 14.04
Total Debt to Total Equity 0.00
EBITDA Margin 33.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 435.64
ROE % 18.55
ROCE % 24.84
Total Debt to Total Equity 0.00
EBITDA Margin 39.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 360.86
ROE % 20.88
ROCE % 27.99
Total Debt to Total Equity 0.00
EBITDA Margin 41.50
Particulars MAR 2025 (Values in Cr)
Book Value / Share 592.08
ROE % 11.62
ROCE % 15.83
Total Debt to Total Equity 0.00
EBITDA Margin 40.27
Particulars MAR 2024 (Values in Cr)
Book Value / Share 546.13
ROE % 12.31
ROCE % 16.65
Total Debt to Total Equity 0.00
EBITDA Margin 37.80
Particulars MAR 2023 (Values in Cr)
Book Value / Share 482.90
ROE % 10.27
ROCE % 13.96
Total Debt to Total Equity 0.00
EBITDA Margin 33.25
Particulars MAR 2022 (Values in Cr)
Book Value / Share 435.68
ROE % 18.56
ROCE % 24.85
Total Debt to Total Equity 0.00
EBITDA Margin 39.42
Particulars MAR 2021 (Values in Cr)
Book Value / Share 360.86
ROE % 20.88
ROCE % 27.99
Total Debt to Total Equity 0.00
EBITDA Margin 41.50
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2556.20
Total Assets 11224.92
Total Liabilities 11224.92
Total Equity 9150.74
Share Outstanding 164756423
Price to Book Ratio 2.69
Return on Assets (%) 6.22
Return on Capital (%) 7.42
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1839.43
Total Assets 10661.24
Total Liabilities 10661.24
Total Equity 8723.84
Share Outstanding 164708123
Price to Book Ratio 3.37
Return on Assets (%) 7.24
Return on Capital (%) 8.54
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3770.67
Total Assets 8777.53
Total Liabilities 8777.53
Total Equity 7958.72
Share Outstanding 164700823
Price to Book Ratio 2.63
Return on Assets (%) 8.89
Return on Capital (%) 9.81
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3093.44
Total Assets 7833.62
Total Liabilities 7833.62
Total Equity 7157.62
Share Outstanding 164302723
Price to Book Ratio 7.50
Return on Assets (%) 15.46
Return on Capital (%) 16.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3005.75
Total Assets 6496.08
Total Liabilities 6496.08
Total Equity 5903.24
Share Outstanding 163592923
Price to Book Ratio 6.87
Return on Assets (%) 15.34
Return on Capital (%) 16.88
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2432.62
Total Assets 10421.61
Total Liabilities 10421.61
Total Equity 9755.10
Share Outstanding 164756423
Price to Book Ratio 2.69
Return on Assets (%) 10.45
Return on Capital (%) 11.17
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1598.54
Total Assets 9541.08
Total Liabilities 9541.08
Total Equity 8995.28
Share Outstanding 164710523
Price to Book Ratio 3.37
Return on Assets (%) 10.93
Return on Capital (%) 11.59
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3766.99
Total Assets 8773.17
Total Liabilities 8773.17
Total Equity 7953.29
Share Outstanding 164700823
Price to Book Ratio 2.63
Return on Assets (%) 8.84
Return on Capital (%) 9.75
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3085.80
Total Assets 7834.14
Total Liabilities 7834.14
Total Equity 7158.22
Share Outstanding 164302723
Price to Book Ratio 7.50
Return on Assets (%) 15.47
Return on Capital (%) 16.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3005.20
Total Assets 6496.05
Total Liabilities 6496.05
Total Equity 5903.28
Share Outstanding 163592923
Price to Book Ratio 6.87
Return on Assets (%) 15.34
Return on Capital (%) 16.88
Particulars MAR 2025 (Values in Cr)
Net Income 1062.65
Cash from Operations 1268.53
Cash from Investing 1704.73
Cash from Financing -433.47
Net change in Cash 2185.99
Free Cash Flow 1653.07
Particulars MAR 2024 (Values in Cr)
Net Income 1132.54
Cash from Operations 1302.94
Cash from Investing -1756.91
Cash from Financing -799.41
Net change in Cash -1559.53
Free Cash Flow 1692.87
Particulars MAR 2023 (Values in Cr)
Net Income 1054.58
Cash from Operations 674.83
Cash from Investing 1208.18
Cash from Financing 14.91
Net change in Cash 1587.07
Free Cash Flow 895.76
Particulars MAR 2022 (Values in Cr)
Net Income 1618.55
Cash from Operations 1197.27
Cash from Investing -1002.62
Cash from Financing 34.89
Net change in Cash -176.95
Free Cash Flow 1708.60
Particulars MAR 2021 (Values in Cr)
Net Income 1334.81
Cash from Operations 916.35
Cash from Investing -1524.00
Cash from Financing 1238.46
Net change in Cash 319.38
Free Cash Flow 1145.13
Particulars MAR 2025 (Values in Cr)
Net Income 1465.58
Cash from Operations 1425.84
Cash from Investing 1578.19
Cash from Financing -339.54
Net change in Cash 2312.32
Free Cash Flow 1560.95
Particulars MAR 2024 (Values in Cr)
Net Income 1405.49
Cash from Operations 1452.02
Cash from Investing -2923.92
Cash from Financing -7.39
Net change in Cash -1795.35
Free Cash Flow 1685.61
Particulars MAR 2023 (Values in Cr)
Net Income 1048.40
Cash from Operations 678.78
Cash from Investing 1208.22
Cash from Financing 14.91
Net change in Cash 1591.03
Free Cash Flow 899.70
Particulars MAR 2022 (Values in Cr)
Net Income 1619.04
Cash from Operations 1197.79
Cash from Investing -1010.22
Cash from Financing 34.89
Net change in Cash -184.04
Free Cash Flow 1709.12
Particulars MAR 2021 (Values in Cr)
Net Income 1334.85
Cash from Operations 916.35
Cash from Investing -1524.54
Cash from Financing 1238.46
Net change in Cash 318.84
Free Cash Flow 1145.13
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.40 12.82 1.71 240.63 30.00 / 69.50
BLISS GVS PHARMA LTD 155.80 15.41 1.56 1643.65 105.05 / 190.65
CIPLA LTD 1589.65 23.81 4.11 128404.63 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 317.55 8.94 2.57 934.58 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.40 17.07 4.96 240.63 30.00 / 69.50
AMRUTAJAN HEALTH LTD 688.80 36.52 6.09 1991.36 548.05 / 840.55
ASTRAZENECA PHARMA IND LT 8469.45 100.12 27.48 21173.63 6222.35 / 10653.05
BLISS GVS PHARMA LTD 155.80 23.29 1.55 1643.65 105.05 / 190.65

GLAND PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1871.50 -0.81 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 1906.40
  • 26 Days 1937.30
  • 10 Days 1925.60
  • 50 Days 1891.80
  • 12 Days 1930.60
  • 100 Days 1804.00
  • 20 Days 1939.80
  • 200 Days 1748.40
1896.97 PIVOT

First Support

1864.93

First Resistance

1918.83

Second Support

1843.07

Second Resistance

1950.87

Third Support

1811.03

Third Resistance

1972.73

RSI

36.71

ADX

9.96

MACD

-6.75

Williams % R

-87.00

Commodity Channel Index (CCI)

-198.28

Date

2025-08-29

Week

130094.00

Same Day

65102.00

Month

166645.00

1 Year

0.82

3 Year

0.47

Over 1 Month

-10.96%

down

Over 1 Year

1.21%

down

Over 3 Months

18.58%

down

Over 3 Years

-7.19%

down

Over 6 Months

20.52%

down

Over 5 Years

0.56%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

GLAND PHARMA LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
7.92%
Promoter Holdings
51.83%
FII
7.38%
DII
32.85%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Fosun Pharma Industrial Pte. Ltd 8.5393894E7 (51.83%) Shareholding of Promoter and Promoter Group
Hdfc Mutual Fund - Hdfc Mid-cap Fund 1.0832715E7 (6.57%) Public Shareholding
Mirae Asset Large & Midcap Fund 1.0286158E7 (6.24%) Public Shareholding
Nippon Life India Trustee Ltd-a/c Nippon India Growth Fund 1.0068179E7 (6.11%) Public Shareholding
Icici Prudential India Opportunities Fund 8375667.0 (5.08%) Public Shareholding
Sbi Large & Midcap Fund 4797550.0 (2.91%) Public Shareholding
Government Pension Fund Global 2460169.0 (1.49%) Public Shareholding
Uti-flexi Cap Fund 1905325.0 (1.16%) Public Shareholding
Regal Gesture Limited 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Lustrous Star Limited 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Fosun Industrial Co Limited 10.0 (0.0%) Shareholding of Promoter and Promoter Group
Ample Up Limited 10.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

GLAND PHARMA LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Aug 2025 18.0 Final 14 Aug 2025 Equity shares
16 Aug 2024 20.0 Final 16 Aug 2024 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Aug 2025 18.0 Final 14 Aug 2025 Equity shares
16 Aug 2024 20.0 Final 16 Aug 2024 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

GLAND PHARMA LIMITED Share Price

Gland Pharma Limited was incorporated as Gland Pharma Private Limited', a private limited company on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the Company was changed to Gland Pharma Limited' and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. The Company is primarily engaged in manufacturing injectable formulations.

Established in Hyderabad, India, Company has evolved into a prominent entity in the global generic injectables market, with operations extending to over 60 countries including the United States, Europe, Canada, Australia, and India. Primarily functioning under a B2B model, the company provides comprehensive services such as contract development, dossier compilation, technology transfer, and manufacturing across various delivery systems.

Over the years, the company has made substantial investments in the companies manufacturing infrastructure to support the product portfolio needs and reach. The company has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 42 production lines and three API facilities. The companies API facilities provide with in-house manufacturing capabilities for critical APIs, enabling the company to control costs and quality and mitigate supply chain related risks around the key products. The companies capabilities as a vertically integrated company include internal research and development (R&D) expertise, robust manufacturing capabilities, a strict quality assurance system, extensive regulatory experience and established marketing and distribution relationships.

As of March 31, 2020, the company along with partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval. The 265 ANDA filings comprise 189 ANDA filings for sterile injectables, 50 for oncology and 26 for ophthalmics related products. Out of these 265 ANDA filings, 100 represent ANDAs owned by the company, of which 63 ANDA filings are approved and 37 are pending approval. As of the same date, the company along with partners had a total of 1,415 product registrations, comprising 368 product registrations in the United States, Europe, Canada and Australia, 54 in India and 993 in the Rest of the world. The company also has a consistent regulatory compliance track record and all the facilities are approved by the USFDA from whom the company have had no warning letters since the inception of each facility. Other key regulatory agencies for which certain of our facilities have approvals include MHRA (UK), TGA (Australia), ANVISA (Brazil), AGES (Austria) and BGV Hamburg (Germany).

During the year 2020-21, the Company has incorporated Gland Pharma International Pte. Ltd., a Wholly-owned Subsidiary in Singapore. It has incurred capital expenditure of Rs. 2,287.76 million at its manufacturing facilities at Dundigal, Pashamylaram, VSEZ and Pharmacity. It has issued and allotted 8,333,333 fully paid-up equity shares in the Initial Public Offer during November, 2020.

During FY 2022, the Company launched 47 product SKUs of 28 molecules like Micafungin, Ziprasidone, Bivalirudin RTU and Olapatadine Ophthalmic (OTC). As of March 31, 2022, it along with the partners had 284 ANDA filings in the US, of which 234 were approved and 50 were pending approval. Out of these, 115 were owned by the Company with 85 approvals and 30 pending for approval. It had manufacturing capacity for finished formulations of approximately 767 million units per annum. It filed 21 ANDAs, 5 DMFs and received 32 ANDA approvals. It signed an agreement to supply upto 252 million doses of RDIF's Sputnik V COVID-19 vaccine. It purchased assets of Vitane Biologics, Hyderabad based biopharmaceutical company.

On 27th April, 2023, Gland Pharma International Pte. Ltd., Wholly Owned Subsidiary of the Company acquired Phixen SAS and 3 holding companies in Cenexi for a purchase consideration costing Euro 114,259,004.44 and repaid a loan of Euro 79,457,194.11 on behalf of the Sellers through Share Purchase Agreement dated 6th January, 2023 and as a result, Phixen SAS and the Cenexi Holding Entities became the Wholly Owned step-down Subsidiaries of the Company, which in turn resulted in indirect acquisition of 7 subsidiaries of Cenexi, a) Cenexi SAS, (b) Cenexi Services SAS, (c) Cenexi HSC SAS, (d) Cenexi 2 SASU, (e) Cenexi 3 SASU, (f) Cenexi Laboratories Thissen SA and (g) Phineximmo SA. 'Dexrazoxane' the first product was launched in China during the year 2023.

The Company launched Eribulin as its first major complex product in May, 2024. The Company commissioned a new high-capacity ampoule line, adding an annual capacity of 40 to 50 Million units at Fontenay, France in FY 2025.

Parent organization MNC Associate
NSE symbol GLAND
Founded 1978
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Gland Pharma Ltd?

Answer Field

Gland Pharma Ltd share price is for NSE ₹ 1,871.50 & for BSE ₹ 1,885.00 as on Aug 29 2025 03:30 PM.

What is the Market Cap of Gland Pharma Ltd Share?

Answer Field

The market cap of Gland Pharma Ltd for NSE ₹ 30,834.16 & for BSE ₹ 31,056.58 as on Aug 29 2025 03:30 PM.

What is the 52 Week High and Low of Gland Pharma Ltd?

Answer Field

The 52 Week High and Low of Gland Pharma Ltd for NSE is ₹ 2,131.00 and ₹ 1,277.80 and for BSE is ₹ 2,130.00 and ₹ 1,200.00.

What is 1 year return for Gland Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 1.21%.

What is the P/E Ratio of Gland Pharma Ltd Share?

Answer Field

As on Aug 29 2025 03:30 PM the price-to-earnings (PE) ratio for Gland Pharma Ltd share is 27.07.

What is the PB ratio of Gland Pharma Ltd Share?

Answer Field

As on Aug 29 2025 03:30 PM, the price-to-book (PB) ratio for Gland Pharma Ltd share is 592.09.

How to Buy Gland Pharma Ltd Share?

Answer Field

You can trade in Gland Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gland Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Gland Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gland Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91